Galectin Therapeutics Inc (GALT)

Jan 29, 2025

Liver Cirrhosis Market Forecasted for Strong Growth from 2025 - openPR

Jan 29, 2025

Jan 29, 2025

Galectin Therapeutics Inc. Reports Results from 2024 Annual Meeting in Recent 8-K Filing - Defense World

Jan 29, 2025

Jan 28, 2025

Galectin drops as trial for lead asset fails in MASH - MSN

Jan 28, 2025

Jan 28, 2025

Galectin Therapeutics shareholders elect directors, ratify auditor - MSN

Jan 28, 2025

Jan 28, 2025

Galectin Therapeutics shareholders elect directors, ratify auditor By Investing.com - Investing.com Nigeria

Jan 28, 2025

Jan 25, 2025

Galectin Therapeutics (NASDAQ: GALT) 8-K Filing Reveals Positive Results from NAVIGATE Trial - Defense World

Jan 25, 2025

Jan 25, 2025

Barclays PLC Purchases 21,598 Shares of Galectin Therapeutics Inc. (NASDAQ:GALT) - Defense World

Jan 25, 2025

Jan 23, 2025

Galectin Therapeutics Unveils Promising NAVIGATE Trial Results - TipRanks

Jan 23, 2025

Jan 21, 2025

HC Wainwright & Co. Downgrades Galectin Therapeutics (GALT) - MSN

Jan 21, 2025

Jan 18, 2025

Galectin Therapeutics (NASDAQ: GALT) Updates Corporate Presentation and Discloses Forward-Looking StatementsGalectin Therapeutics Inc. (the “Company”) updated its corporate presentation on January 13, 2025, which will be utilized in interactions such - Defense World

Jan 18, 2025

Jan 18, 2025

Galectin Therapeutics Inc. (NASDAQ:GALT) Shares Purchased by Wealth Enhancement Advisory Services LLC - Defense World

Jan 18, 2025

Jan 15, 2025

Galectin Therapeutics Target of Unusually High Options Trading (NASDAQ:GALT) - MarketBeat

Jan 15, 2025

Jan 11, 2025

Comparing Galectin Therapeutics (NASDAQ:GALT) and Avenue Therapeutics (NASDAQ:ATXI) - Defense World

Jan 11, 2025

Jan 10, 2025

Galectin Therapeutics to Present at the 2025 MASH-TAG Conference - The Manila Times

Jan 10, 2025

Jan 10, 2025

Galectin Therapeutics to Present Breakthrough NAVIGATE Trial Results at MASH-TAG 2025 Conference - StockTitan

Jan 10, 2025

Jan 10, 2025

Galectin Therapeutics Inc. (NASDAQ:GALT) Shares Bought by Barclays PLC - Defense World

Jan 10, 2025

Jan 08, 2025

Geode Capital Management LLC Acquires 20,817 Shares of Galectin Therapeutics Inc. (NASDAQ:GALT) - Defense World

Jan 08, 2025

Jan 03, 2025

Galectin Therapeutics Inc. (NASDAQ:GALT) Shares Bought by State Street Corp - Defense World

Jan 03, 2025

Dec 31, 2024

Galectin Therapeutics director Harold Shlevin purchases $7,539 in common stock - Investing.com Nigeria

Dec 31, 2024

Dec 31, 2024

Galectin Therapeutics Director Increases Stake Amid Strong Momentum, Despite Trial Setbacks - HPBL

Dec 31, 2024

Dec 31, 2024

Galectin Therapeutics (NASDAQ:GALT) Lowered to “Sell” Rating by StockNews.com - Defense World

Dec 31, 2024

Dec 31, 2024

Galectin Therapeutics (NASDAQ:GALT) Downgraded by StockNews.com to "Sell" - MarketBeat

Dec 31, 2024

Dec 30, 2024

Galectin Therapeutics Inc. (NASDAQ:GALT) Short Interest Up 41.1% in December - MarketBeat

Dec 30, 2024

Dec 30, 2024

North American Morning Briefing : Boeing Stock -2- - Marketscreener.com

Dec 30, 2024

Dec 30, 2024

Galectin Therapeutics Inc. (NASDAQ:GALT) Shares Sold by Sanctuary Advisors LLC - Defense World

Dec 30, 2024

Dec 30, 2024

H.C. Wainwright cuts Galectin stock rating to Neutral By Investing.com - Investing.com Canada

Dec 30, 2024

Dec 28, 2024

Galectin Therapeutics (NASDAQ:GALT) Given “Neutral” Rating at HC Wainwright - Defense World

Dec 28, 2024

Dec 27, 2024

HC Wainwright Reiterates Neutral Rating for Galectin Therapeutics (NASDAQ:GALT) - MarketBeat

Dec 27, 2024

Dec 27, 2024

Eldred Kary buys $11,044 in Galectin Therapeutics shares By Investing.com - Investing.com Australia

Dec 27, 2024

Dec 26, 2024

Joel Lewis Sells 56,000 Shares of Galectin Therapeutics Inc. (NASDAQ:GALT) Stock - MarketBeat

Dec 26, 2024

Dec 26, 2024

Insider Selling: Galectin Therapeutics Inc. (NASDAQ:GALT) Insider Sells 13,654 Shares of Stock - MarketBeat

Dec 26, 2024

Dec 26, 2024

Galectin Therapeutics Inc. (NASDAQ:GALT) CFO Sells $35,600.00 in Stock - MarketBeat

Dec 26, 2024

Dec 26, 2024

Eldred Kary buys $11,044 in Galectin Therapeutics shares - Investing.com India

Dec 26, 2024

Dec 26, 2024

Galectin Therapeutics director Kevin Freeman acquires $8,134 in stock By Investing.com - Investing.com Australia

Dec 26, 2024

Dec 26, 2024

Galectin Therapeutics director Kevin Freeman acquires $8,134 in stock - Investing.com India

Dec 26, 2024

Dec 26, 2024

Galectin Therapeutics CEO Lewis Joel sells $49,610 in stock By Investing.com - Investing.com Canada

Dec 26, 2024

Dec 26, 2024

Galectin Therapeutics director Richard Zordani buys $8,164 in stock By Investing.com - Investing.com Nigeria

Dec 26, 2024

Dec 26, 2024

Galectin Therapeutics’ chief medical officer sells $12,044 in shares By Investing.com - Investing.com Nigeria

Dec 26, 2024

Dec 26, 2024

Galectin Therapeutics director Richard Zordani buys $8,164 in stock - Investing.com India

Dec 26, 2024

Dec 26, 2024

Galectin therapeutics CFO Jack Callicutt sells $35,492 in stock By Investing.com - Investing.com Canada

Dec 26, 2024

Dec 26, 2024

Galectin Therapeutics CEO Lewis Joel sells $49,610 in stock - Investing.com

Dec 26, 2024

Dec 26, 2024

Galectin Therapeutics' chief medical officer sells $12,044 in shares - Investing.com

Dec 26, 2024

Dec 23, 2024

Liver Cirrhosis Therapeutics Market Size in the 7MM was ~USD 3,100 Million in 2023, is further anticipated to increase with a siginificant CAGR by 2034 and estimated DelveInsight - Barchart

Dec 23, 2024

Dec 23, 2024

Liver Cirrhosis Therapeutics Market Size in the 7MM was ~USD - openPR

Dec 23, 2024

Dec 23, 2024

Galectin Therapeutics Announces Positive Results from NAVIGATE Clinical Trial - Defense World

Dec 23, 2024

Dec 20, 2024

Belapectin shows promise in liver disease trial - Investing.com India

Dec 20, 2024

Dec 20, 2024

Dow Surges Over 600 Points, Gold Jumps 1.5% - Benzinga

Dec 20, 2024

Dec 20, 2024

Galectin Therapeutics Shares Drop 54% After Treatment Misses Trial Endpoint - MarketWatch

Dec 20, 2024